Recursion Pharmaceuticals
(NASDAQ) RXRX
Recursion Pharmaceuticals Financials at a Glance
Market Cap
$1.56B
Revenue (TTM)
$66.29M
Net Income (TTM)
$559.78M
EPS (TTM)
$-1.20
P/E Ratio
-2.44
Dividend
$0.00
Beta (Volatility)
2.33 (High)
Dividend
$0.00
Beta (Volatility)
2.33 (High)
Price
$2.88
Volume
249,184
Open
$2.92
Price
$2.88
Volume
249,184
Open
$2.92
Previous Close
$2.93
Daily Range
$2.85 - $2.94
52-Week Range
$2.80 - $7.18
Dividend
$0.00
Beta (Volatility)
2.33 (High)
Price
$2.88
Volume
249,184
Open
$2.92
Previous Close
$2.93
Daily Range
$2.85 - $2.94
52-Week Range
$2.80 - $7.18
RXRX News
RXRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Recursion Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
600
CEO
Najat Khan, PhD
Website
www.recursion.comHeadquarters
Salt Lake City, UT 84101, US
RXRX Financials
Key Financial Metrics (TTM)
Gross Margin
-34%
Operating Margin
-9%
Net Income Margin
-8%
Return on Equity
-57%
Return on Capital
-48%
Return on Assets
-42%
Earnings Yield
-40.98%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.56B
Shares Outstanding
530.76M
Volume
249.18K
Avg. Volume
14.25M
Financials (TTM)
Gross Profit
$46.27M
Operating Income
$648.13M
EBITDA
$559.38M
Operating Cash Flow
$371.81M
Capital Expenditure
$6.47M
Free Cash Flow
$378.28M
Cash & ST Invst.
$743.29M
Total Debt
$77.97M
Recursion Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$6.47M
-56.1%
Gross Profit
$6.02M
+15.0%
Gross Margin
-92.99%
N/A
Market Cap
$1.56B
N/A
Market Cap/Employee
$1.94M
N/A
Employees
800
N/A
Net Income
$117.50M
+42.0%
EBITDA
$108.83M
+40.5%
Quarterly Fundamentals
Net Cash
$582.10M
+42.8%
Accounts Receivable
$13.59M
-70.5%
Inventory
$0.00
N/A
Long Term Debt
$50.02M
-31.0%
Short Term Debt
$22.35M
+9.4%
Return on Assets
-41.79%
N/A
Return on Invested Capital
-48.38%
N/A
Free Cash Flow
$81.36M
+39.2%
Operating Cash Flow
$81.10M
+38.5%